| Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease FJ Alharbi, S Baig, C Auray-Blais, M Boutin, DG Ward, N Wheeldon, ... Journal of inherited metabolic disease 41, 239-247, 2018 | 32 | 2018 |
| Diagnosis and treatment of the cardiovascular consequences of Fabry disease S Baig, R Vijapurapu, F Alharbi, S Nordin, R Kozor, J Moon, B Bembi, ... QJM: An International Journal of Medicine 112 (1), 3-9, 2019 | 20 | 2019 |
| The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease FJ Alharbi, S Baig, SB Rambhatla, R Vijapurapu, C Auray-Blais, M Boutin, ... Clinica Chimica Acta 500, 120-127, 2020 | 16 | 2020 |
| A novel rapid MALDI-TOF-MS-based method for measuring urinary globotriaosylceramide in Fabry patients FJ Alharbi, T Geberhiwot, DA Hughes, DG Ward Journal of The American Society for Mass Spectrometry 27 (4), 719-725, 2016 | 10 | 2016 |
| Systemic Immune-Inflammation Index in Relation to Diabetes Markers in Saudi Adults: A Retrospective Study GS Aljuraiban, FJ Alharbi, AO Aljohi, AZ Almeshari, MN Alotaibi, ... Medicina 60 (3), 442, 2024 | | 2024 |
| Clinical utility of total concentration of globotriaosylsphingosine (Lyso-Gb3) and its analogues in diagnosing Fabry disease FJ Alharbi, S Baig, T Geberhiwot Molecular Genetics and Metabolism 129 (2), S19, 2020 | | 2020 |
| The use of globotriaosylsphingosine to detect and monitor Fabry Disease FJ Alharbi University of Birmingham, 2016 | | 2016 |
